Our findings suggest that AR-R17779 as a monotherapy was effective as a stimulator of CHRNA7 signaling, which activated myeloid immune cells leading to increased T cell–mediated tumor clearance to reduced tumor burden and increased survival. This evidence concerns the gene CHRNA7 and neoplasm.